Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin
Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin
复制标题
DOI：
10.1016/s1388-9842(03)00005-9
复制
发表时间：
2003-08-01
影响因子：
18.2
通讯作者：
O'Connor, CM
中科院分区：
文献类型：
--
作者：
Serebruany, VL;Glassman, AH;O'Connor, CM
临床抑郁症已被确定为冠状动脉疾病患者死亡率增加的独立危险因素。血小板活性增强被认为是造成这种不良关联的机制。已知选择性血清素再摄取抑制剂（SSRI）会抑制接受冠状动脉支架置入术的患者的血小板。我们试图确定与 SSRIs 联合治疗是否会对已经接受过阿司匹林治疗的充血性心力衰竭 (CHF) 患者产生额外的抗血小板益处。共有88名患者的左心室射血分数（LVEF）
Clinical depression has been identified as an independent risk factor for increased mortality in patients with coronary artery disease. Enhanced platelet activity has been suggested as the mechanism responsible for this adverse association. Selective serotonin reuptake inhibitors (SSRIs) are known to inhibit platelets in patients undergoing coronary stenting. We sought to determine whether concomitant therapy with SSRIs would yield additional anti-platelet benefit in patients with congestive heart failure (CHF) already treated with antecedent aspirin. A total of 88 patients with left ventricular ejection fraction (LVEF)